Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;22(5):263-274.
doi: 10.2217/pgs-2020-0112. Epub 2021 Mar 4.

Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients

Ina Liko  1   2 , Yee Ming Lee  2 , Danielle L Stutzman  2   3   4 , Allison B Blackmer  2   3   5 , Kimberly M Deininger  1 , Ann M Reynolds  5   6 , Christina L Aquilante  1
Affiliations

Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients

Ina Liko et al. Pharmacogenomics. 2021 Apr.

Abstract

Aim: To assess providers' knowledge, attitudes, perceptions, and experiences related to pharmacogenomic (PGx) testing in pediatric patients. Materials & methods: An electronic survey was sent to multidisciplinary healthcare providers at a pediatric hospital. Results: Of 261 respondents, 71.3% were slightly or not at all familiar with PGx, despite 50.2% reporting prior PGx education or training. Most providers, apart from psychiatry, perceived PGx to be at least moderately useful to inform clinical decisions. However, only 26.4% of providers had recent PGx testing experience. Unfamiliarity with PGx and uncertainty about the clinical value of testing were common perceived challenges. Conclusion: Low PGx familiarity among pediatric providers suggests additional education and electronic resources are needed for PGx examples in which data support testing in children.

Keywords: children; pediatric; perspective; pharmacogenetic; pharmacogenomic; provider; testing.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This publication is supported in part by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535. The contents of this article are the authors’ sole responsibility and do not necessarily represent official NIH views. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No funded writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Providers’ familiarity with pharmacogenomic testing in the pediatric population.
Figure 2.
Figure 2.. Providers’ (n = 257) perception of pediatric specialties where pharmacogenomics has the most clinical use.
Figure 3.
Figure 3.. Pharmacogenomic resources providers (n = 253) have used, would like to use, and do not perceive they need.
See this image and copyright information in PMC

References

    1. Collins FS, Varmus H. A new initiative on precision medicine. N. Engl. J. Med. 372(9), 793–795 (2015). - PMC - PubMed
    1. Roden DM, McLeod HL, Relling MV et al. Pharmacogenomics. Lancet 394(10197), 521–532 (2019). - PMC - PubMed
    1. Dunnenberger HM, Crews KR, Hoffman JM et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 55, 89–106 (2015). - PMC - PubMed
    1. Rahawi S, Naik H, Blake KV et al. Knowledge and attitudes on pharmacogenetics among pediatricians. J. Hum. Genet. 65(5), 437–444 (2020). - PMC - PubMed
    1. Ramsey LB, Ong HH, Schildcrout JS et al. Prescribing prevalence of medications with potential genotype-guided dosing in pediatric patients. JAMA Netw. Open 3(12), e2029411 (2020). - PMC - PubMed

Publication types

MeSH terms